Vaccitech plc (VACC) News

Vaccitech plc (VACC): $4.61

0.16 (+3.60%)

POWR Rating

Component Grades













Add VACC to Watchlist
Sign Up

Industry: Biotech


of 505

in industry

Filter VACC News Items

VACC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest VACC News From Around the Web

Below are the latest news stories about Vaccitech plc that investors may wish to consider to help them evaluate VACC as an investment opportunity.

DeepMind Co-Founder Suleyman Exits Google for VC Firm Greylock

(Bloomberg) -- The co-founder of Google’s high-profile DeepMind artificial intelligence lab has left Alphabet Inc. to join venture capital firm Greylock Partners, following a turbulent tenure.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapA Nor’easter Approaching New York Risks Becoming a Bomb CycloneMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksNvidia Quietly Prepares to Abandon $40 Billion Arm BidTech Giants Rally Amid Bullish Outlo

Yahoo | January 21, 2022

Vaccitech Plc (VACC) Gets a Buy Rating from H.C. Wainwright

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vaccitech Plc (VACC – Research Report), with a price target of $23.00. The company's shares closed last Tuesday at $9.98. According to, Chen is a 5-star analyst with an average return of 24.0% and a 37.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. Currently, the analyst consensus on Vaccitech Plc is a Moderate Buy with an average price target of $23.00.

Christine Brown on TipRanks | January 19, 2022

Vaccitech, Cancer Research UK, Ludwig begins dosing in phase 1/2a lung cancer trial

Cancer Research UK, Vaccitech (VACC) and the Ludwig Institute for Cancer Research said the first patient was dosed in a phase 1/2a trial called MAGE trial evaluating

Seeking Alpha | January 18, 2022

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and

Yahoo | January 18, 2022

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader ("KOL") event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25 th at 8:30 a.m. EST. Featured speakers: Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King''s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network. Dr. Henry L. Y. Chan, head of the Divis...

Benzinga | January 13, 2022

Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | January 10, 2022

Vaccitech plc (NASDAQ:VACC) Director Acquires $99,700.00 in Stock

Vaccitech plc (NASDAQ:VACC) Director Robin Wright purchased 10,000 shares of the business’s stock in a transaction on Wednesday, December 22nd. The stock was purchased at an average cost of $9.97 per share, with a total value of $99,700.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. […]

Dakota Financial News | December 24, 2021

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Allogene Therapeutics (ALLO) and Vaccitech Plc (VACC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inovio Pharmaceuticals (INO – Research Report), Allogene Therapeutics (ALLO – Research Report) and Vaccitech Plc (VACC – Research Report). Inovio Pharmaceuticals (INO) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company's shares closed last Tuesday at $5.91, close to its 52-week low of $5.75. According to TipRanks.

Austin Angelo on TipRanks | December 15, 2021

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ:

Business Insider Markets | December 14, 2021

Vaccitech shells out $40M to acquire Avidea, gaining antigen, immunomodulator platform

No summary available.

Seeking Alpha | December 13, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5443 seconds.